

US Tumor Marker Testing Market Shares and Segment Forecasts 2017-2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

https://marketpublishers.com/r/UE8341E7508EN.html

Date: December 2017 Pages: 620 Price: US\$ 9,800.00 (Single User License) ID: UE8341E7508EN

Abstracts

Complete report \$9,800. DataPack (test volumes, sales forecasts, supplier shares) \$6,400. Highlights

Comprehensive 620-page analysis of the US tumor marker testing market.

Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.

Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.



Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

- 1. MARKET O5ER6EW
- 2. WORLDW1DE MARKET STRUCTURE
- 3. WORLDW1DE MARKET S1ZE AND GROWTH

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. 1nstrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. 1nternal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology



- 1. BREAST CANCER
- 2. LUNG CANCER
- 3. COLON AND RECTUM CANCER
- 4. PROSTATE CANCER
- 5. STOMACH CANCER
- 6. LEUKEM1A
- 7. LYMPHOMA
- 8. ORAL CANCER
- 9. SK1N CANCER
- 10. UTER1NE CANCER
- 11. O5AR1AN CANCER
- 12. BLADDER CANCER

B. Major Current And Emerging Cancer Diagnostic Tests

- 1. 1NTRODUCT1ON
- 2. TUMOR MARKER CLASS1F1CAT1ON
- 3. ACTH
- 4. ALPHA-FETOPROTE1N (AFP)
- 5. BETA-2 M1CROGLOBUL1N
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. CALC1TON1N
- 10. CARC1NOEMBR1ON1C ANT1GEN (CEA)
- 11. ESTROGEN AND PROGESTERONE RECEPTORS
- 12. FERR1T1N
- 13. GASTR1N
- 14. HUMAN CHOR1ON1C GONADOTROP1N (HCG)
- 15. 1NSUL1N
- 16. NSE
- 17. OCCULT BLOOD
- 18. PAP SMEAR/HP5
- 19. PROSTAT1C AC1D PHOSPHATASE (PAP)
- 20. PROSTATE-SPEC1F1C ANT1GEN (PSA)
- 21. SQUAMOUS CELL CARC1NOMA ANT1GEN (SCC)
- 22. T AND B LYMPHOCYTES
- 23. TDT
- 24. THYROGLOBUL1N
- 25. T1SSUE POLYPEPT1DE ANT1GEN (TPA)
- 26. B1OCHEM1CAL TUMOR MARKERS



27. ONCOGENES Abl/abl-bcr A1B1 BCL-2 BRCA1 CD44 C-fos C-myb C-myc **CYP-17** Erb-B HPC1 N-myc P40 P51 P53 P1K3CA PT1-1 Ras Reg Sis Src 28. POLYPEPT1DE GROWTH FACTORS **Basic Fibroblast Growth Factor** Beta-TGF Cachectin (TNT) Calmodulin **ECFR** Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor-Alpha 29. ECTOP1C HORMONES **30. COLONY ST1MULAT1NG FACTORS** 31. LYMPHOK1NES Alpha-1nterferon **B Cell Growth Factors**

B Cell Growth Factor (BCGF)





Gamma-1nterferon 1nterleukin-1 (1L-1) Macrophage Activating Factor 32. 1MMUNOH1STOCHEM1CAL STA1NS 33. EMERG1NG TUMOR MARKERS N-Acetylglucosamine Actin Alpha-Actin Antineuronal Antibodies 7B2 B72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA CA 72-4/TAG-72 CA CA-242 CA-549 CAM CAR-3 Cathepsin-D Chromogranin A and B Cluster 1 Antigen Cluster-5/5A Antigen CTA CU18 **DR-70** DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH (1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15



Glucagon Glycoamines H23 Her-2 Human Carcinoma Antigen HPA HSP27 **1ntermediate Filaments** Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein** Neurofilaments 5imentin KA **Kinases** KP16D3 LA1 Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA) Multiple Tumor Suppressor Myosin **NEA-130** NMP22 OA-519 **Opioid Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA) Placental Lactogen **PR92** Proliferative 1ndex, Ki-67



Px RB 1nactivation/Deletion Ret SCCL Selectin Sialic AcHSP27

1ntermediate Filaments Cytokeratins/CK18/Cyfra 21-1 Desmin Gliofibrillary Acid Protein Neurofilaments 5imentin

KA

Kinases

KP16D3

LA1

Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA



Mucin Cancer Antigen (MCA) Multiple Tumor Suppressor Myosin

NEA-130

NMP22

OA-519

Opioid Peptides P-glycoprotein Pancreatic Oncofetal Antigen (POA) Placental Lactogen

PR92

Proliferative 1ndex, Ki-67 Px RB 1nactivation/Deletion Ret

SCCL

Selectin Sialic Acid Sialyl SSEA-1/SL10

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG



TPS

Troponin Tubulin

5CAM

5EGF

5illen

- C. Cancer Diagnostic Testing 1nstrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. MONOCLONAL AND POLYCLONAL ANT1BOD1ES
 - 2. 1MMUNOASSAYS
 - 3. MOLECULAR D1AGNOST1CS
 - 4. CHROMOSOME ANALYS1S
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. ART1F1C1AL 1NTELL1GENCE
 - 6. FLOW CYTOMETRY
 - 7. TWO D1MENS1ONAL GEL ELECTROPHORES1S (2-DGE)
 - 8. B1OSENSORS
- 9. COMPET1NG/COMPLEMENT1NG TECHNOLOG1ES
- E. Personal Testing

VIII. USA CANCER DIAGNOSTICS MARKET

- A. Executive Summary
- B. Business Environment
- C. Market Structure

D. Market Size, Test 5olume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test



IX. COMPETITIVE PROFILES

Abbott AdnaGen/Alere **Agilent Technologies** Applied Gene Technologies Arca Biopharma Beckman Coulter/Danaher **Becton Dickinson Biomedical Diagnostics** bioMerieux **Bio-Rad** CellSearch Cepheid Correlogic Systems/5ermillion **Decode Genetics** Diadexus Diagnocure Diasorin **Eiken Chemical** Elitech Group Enterix Enzo Biochem **Epigenomics Exact Sciences** Fujirebio **Guided Therapeutics** Hologic/Gen-Probe Kreatech/Leica Kyowa Medex Mackay Life Sciences **Myriad Genetics** OncoLab **Ortho-Clinical Diagnostics** Panacea Pharmaceuticals **Polartechnics** Polymedco PreMD Qiagen



Quest Diagnostics Radient Pharmaceuticals Roche Scienion Sequenom Siemens Healthcare Takara Bio Targeted Diagnostics & Therapeutics Tosoh Thermo Seridex Wako Pure Chemicals Wallac/PE Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

L1ST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing 1nsulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HP5 Tests Major Companies Developing or Marketing PAP Tests



Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests Biochemical Markers Potential Applications 1n Cancer Diagnosis Oncogenes Potential Applications 1n Cancer Diagnosis Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications 1n Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications 1n Cancer Diagnosis

1MMUNOHISTOCHEMICAL STAINS POTENTIAL APPLICATIONS IN CANCER DIAGNOSIS

Executive Summary Table: U.S., Total Tumor Marker Test 5olume and Sales Forecast By Market Segment

- U.S., Estimated New Cancer Cases and Deaths
- U.S., Estimated Cancer Death Rates Per 100,000 Population
- U.S., Laboratories Performing Tumor Marker Tests by Market Segment
- U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
- U.S., Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test 50lume
- U.S., Physician Office Laboratories Performing Tumor Marker Tests By Practice Size
- U.S., Total Tumor Marker Test 5olume Forecast by Market Segment
- U.S., All Market Segments Major Tumor Marker Test 5olume Forecast
- U.S., Hospital Laboratories Major Tumor Marker Test 5olume Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Test 5olume Forecast
- U.S., Physician Offices/Group Practices Major Tumor Marker Test 5olume Forecast
- U.S., Cancer Clinics Major Tumor Marker Test 5olume Forecast by Test
- U.S., Total Tumor Marker Sales Forecast by Market Segment
- U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
- U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
- U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
- U.S., ACTH Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., AFP Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Beta-2 Microglobulin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., CA 15-3/27.29 Test 5olume and Diagnostics Sales Forecast by Market Segment U.S., CA 19-9 Test 5olume and Diagnostics Sales Forecast by Market Segment



U.S., CA-125 Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Calcitonin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Cathepsin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., CEA Test 5olume and Diagnostics Sales by Market Segment

U.S., Chromogranin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Colon-specific Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Cytokeratins Test 5olume and Diagnostics Sales Forecast by Market Segment U.S., Estrogen Receptor Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Ferritin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Gastrin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., HCG Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., 1nsulin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., 1nterferons Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., 1nterleukins Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Lymphocyte Subtyping Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., NSE Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Nucleolar Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Occult Blood Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Oncogenes Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Pancreatic Oncofetal Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Smear Test 5olume and Diagnostics Sales Forecast by Market Segment U.S., Parathyroid Hormone Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Progesterone Receptor Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., PSA Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., S-100 Protein Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Serotonin Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Sialic Acid Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., Squamous Cell Carcinoma Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment

U.S., TDT Test 5olume and Diagnostics Sales Forecast by Market Segment U.S., Thymidine Kinase Test 5olume and Diagnostics Sales Forecast by Market Segment



- U.S., Thyroglobulin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., TPA Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Total Tumor Marker Sales By Major Supplier
- U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
- U.S., AFP Testing Market Diagnostics Sales by Major Supplier
- U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
- U.S., CEA Testing Market Diagnostics Sales by Major Supplier
- U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
- U.S., HCG Testing Market Diagnostics Sales by Major Supplier
- U.S., 1nsulin Testing Market Diagnostics Sales by Major Supplier
- U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
- U.S., PAP Testing Market Diagnostics Sales by Major Supplier
- U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
- U.S., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: US Tumor Marker Testing Market Shares and Segment Forecasts 2017-2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
 Product link: https://marketpublishers.com/r/UE8341E7508EN.html
 Price: US\$ 9,800.00 (Single User License / Electronic Delivery)

 If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
 info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/UE8341E7508EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

